Stay updated with semaglutide news today: latest cardiovascular benefits, oral pill updates, combination therapies, safety alerts, and global access.
The latest semaglutide news today focuses on expanded cardiovascular and kidney benefits, progress toward oral formulations, and new combination therapies like cagrilintide. Regulators have also updated safety warnings and supply guidance for this popular GLP-1 medication. Here is a clear breakdown of what the recent headlines mean for patients and researchers.
Cardiovascular and Kidney Benefits Lead Recent Headlines
The SELECT trial showed that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in people with overweight or obesity and existing heart disease. The FLOW trial found a 24% reduction in kidney disease progression in people with type 2 diabetes and chronic kidney disease. These results have led the FDA to expand the approved labels for Wegovy and Ozempic to include cardiovascular risk reduction.
For patients with diabetes and heart disease, semaglutide is no longer just a glucose-lowering drug. It is now a proven cardiovascular protective agent. This shift is one of the biggest stories in metabolic medicine today.
New Formulations: Oral Semaglutide and Higher Doses
Oral semaglutide is already approved as Rybelsus for type 2 diabetes. A higher-dose oral version (25 mg) is being reviewed for obesity and showed about 15% average weight loss in the OASYS 1 trial. Novo Nordisk is also testing a higher-dose injectable (7.2 mg) for people who need more than the standard 2.4 mg dose.
Understanding semaglutide ingredients helps clarify why formulations differ. The active ingredient is always semaglutide, a GLP-1 receptor agonist. Inactive ingredients like absorption enhancers in oral pills change how the drug is delivered.
Combination Therapy: Cagrilintide and Semaglutide
The most anticipated combination is cagrilintide and semaglutide, known as CagriSema. Cagrilintide is an amylin analog that works alongside GLP-1 to reduce appetite. In the REDEFINE 1 phase 3 trial, CagriSema produced up to 22.7% average weight loss after 68 weeks.
Researchers are still refining the cagrilintide semaglutide dosage. The investigational dose is typically 2.4 mg semaglutide plus 2.4 mg cagrilintide, given as a weekly injection. CagriSema is not yet FDA-approved for any indication.
| Therapy | Average Weight Loss (trial) | Cardiovascular Benefit | Approval Status |
|---|---|---|---|
| Semaglutide 2.4 mg (Wegovy) | 14.9% (STEP 1) | 20% MACE reduction (SELECT) | FDA approved for obesity and CV risk reduction |
| Oral semaglutide 25 mg | ~15% (OASYS 1) | Not established | Under FDA review |
| Cagrilintide + semaglutide (CagriSema) | 22.7% (REDEFINE 1) | Not established | Phase 3 |
| Tirzepatide (Zepbound) | 22.5% (SURMOUNT-1) | Not established | FDA approved for obesity |
Safety Updates and Side Effects
The most common semaglutide side effects are nausea, vomiting, diarrhea, and constipation. These usually improve after a few weeks as the body adjusts. Rare but serious risks include pancreatitis, gallbladder disease, and a rare eye condition called NAION.
Some people worry about cancer. Studies have not found a clear causal link between semaglutide and cancer in humans. However, the FDA requires a boxed warning about thyroid C-cell tumors seen in rodents, so people with a personal or family history of medullary thyroid cancer should avoid it.
Global Access: Semaglutide UK and Beyond
In the UK, semaglutide uk access has been phased. The NHS offers Wegovy through specialist weight management services, but eligibility is strict and waiting lists are long. Private prescriptions are widely available but costly.
In the US, supply has improved since 2023, though compounding pharmacies still face scrutiny. The FDA has warned against unapproved compounded semaglutide after several reports of dosing errors.
What This Means for Patients Today
Semaglutide remains a powerful tool for managing type 2 diabetes and obesity, but it is not a cure. It works best with ongoing lifestyle changes, including diet and exercise. Anyone considering semaglutide should talk to a healthcare professional about their personal risks and benefits.
Staying informed about semaglutide news today can help patients and providers make better decisions. For now, the biggest headlines point to broader heart and kidney benefits, more convenient oral options, and exciting combination therapies on the horizon.
Frequently Asked Questions
What is the latest news about semaglutide?
The latest semaglutide news today includes expanded FDA labels for cardiovascular and kidney risk reduction, progress on oral semaglutide for obesity, and phase 3 results for CagriSema. Supply has also improved, but compounded versions remain under regulatory scrutiny.
Is semaglutide linked to cancer?
Studies have not found a clear causal link between semaglutide and cancer in humans. The FDA does require a boxed warning about thyroid C-cell tumors observed in rodents. People with a history of medullary thyroid cancer should not use semaglutide.
Can I get semaglutide in the UK?
Yes, semaglutide is available in the UK through the NHS for eligible patients and via private prescriptions. NHS access for weight management is phased and limited to specialist services. Private costs can be high, and supply varies.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.